Nasdaq

Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America

C-FORWARD is the Second Phase 3 Trial in the Global HCV Development Program; the First Phase 3 Trial, C-BEYOND, is Currently Enrolling Patients in the US and Canada Regimen has Potential Best-in-Class ...
Nasdaq

Atea Pharmaceuticals Advances HCV Treatment with Ongoing Phase 3 C-BEYOND Trial and Promising Phase 2 Results for Bemnifosbuvir and Ruzasvir at EASL 2025

Atea Pharmaceuticals announced the ongoing enrollment in its Phase 3 C-BEYOND trial evaluating the combination of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV). Positive ...
Infectious Disease Advisor

Universal Pediatric HCV Screening May Be Cost-Effective

Universal hepatitis C virus screening was cost-effective compared with risk-based testing in pediatric populations.
koaa

Colorado Springs Housing Authority pauses Section 8 (HCV) assistance

COLORADO SPRINGS — The Executive Director for the Colorado Springs Housing Authority (CSHA) says funding constraints have led to them pausing Section 8, or Housing Choice Voucher (HCV), assistance.